EGFR and neoplasm: Collectively, the data infer that, as for any TKI-resistant mutation, a certain number (clone) of T790M-positive cells may co-exist with sensitizing EGFR-mutations in the heterogenous tumor tissue before treatment with 1G/2G TKIs and hamper the efficacy of these drugs [11,63,66].